

BIOVICA®

Monitoring Metastatic Breast Cancer Treatment with a **Simple Blood Test**

What is **DiviTum® TKa?**

DiviTum® TKa is a FDA-cleared blood test that monitors disease progression and predicts treatment response in metastatic breast cancer. DiviTum TKa works by measuring the activity of an enzyme called Thymidine Kinase (TK).

Here's how DiviTum TKa works

Thymidine Kinase (TK)

TK is an enzyme involved in DNA synthesis and cell division. Cancer cells often have increased DNA synthesis activity, leading to higher levels of TK. Monitoring TK activity can provide insights into how quickly or slowly cancer cells are growing.

Treatment Monitoring

By measuring TK activity in the blood, healthcare providers can assess how well a patient's cancer treatment is working. A lower level of TK activity may indicate that the treatment is effectively slowing down cancer cell growth. On the other hand, an increase in TK activity might suggest that the treatment is becoming less effective, and adjustments to the treatment plan may be necessary.

Personalized Treatment

TK activity measurements can help tailor treatment plans to individual patients. If TK levels show that a treatment is not as effective as expected, your doctor may consider changing the therapy regimen or exploring alternative treatment options.

Who benefits from the DiviTum® TKa test?

DiviTum®TKa monitors disease progression in postmenopausal women previously diagnosed with HR+ metastatic breast cancer.

How can my doctor use DiviTum® TKa to help monitor my breast cancer treatment?

You and your doctor can discuss whether DiviTum TKa is right for you. They can guide you through the process of obtaining and interpreting the test results to ensure the most appropriate and effective treatment plan.

Biovica Cares Patient Assistance Qualification Form

BIOVICA® | DiviTum® TKa

For more information, visit our website at **www.divitum.com**

DiviTum® TKa is CE marked in Europe and FDA 510(k) cleared in the United States. The DiviTum® TKa method and kit are protected under US Patent Nos. 8,765,378 and 9,376,707. Patent protection in 49 countries. DiviTum® is a registered trademark of Biovica International AB

BIOVICA®

Monitoring Metastatic Breast Cancer Treatment with **FDA-cleared DiviTum® TKa**

Timely, accurate information is crucial to monitor your patients' response to treatment. Biovica has designed a blood-based biomarker test called DiviTum® TKa that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer patients.

Thymidine Kinase (TK) plays a key role in DNA synthesis and cell proliferation. Studies have shown that TK activity (TKa) is elevated in actively proliferating cancer. In a proliferating cancer cell, TK is continuously expressed and released into the bloodstream. **The blood-based DiviTum® TKa test does not require a tissue biopsy, can be tested repeatedly during therapy, and can be used as a monitoring tool.** DiviTum TKa can quantify the level of TK released into the circulation from proliferating cells. This generates a DiviTum TKa value, which can offer important insights about the proliferative status of a patient's disease.

DiviTum® TKa helps make **confident treatment decisions**

DiviTum TKa Assurance

Early Assessment

Assess treatment response earlier than traditional methods that rely on changes in tumor volume. Early assessment may allow for quicker adjustments to treatment plans, leading to more effective outcomes.

Personalized Medicine

TKa measurements can help tailor treatment plans to individual patients. Patients with lower TKa may be identified as responders to treatment, while those with higher TKa levels might require alternative therapies or modifications to their current regimens.

Precision Medicine

The precision offered by measuring TKa can potentially reduce overtreatment or undertreatment, ensuring that patients receive the most appropriate and effective therapies based on their unique biological responses.

Reduced Radiation Exposure

For some, reducing the reliance on frequent radiological scans to monitor tumor size could also mean reduced radiation exposure for patients.

Ready to order DiviTum® TKa?

Scan the QR code below.

BIOVICA® | DiviTum® TKa

For more information, visit our website at **www.divitum.com**